Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12041886 | 0.85 | GRM5 (0.39) | — | |
| SCHEMBL12059022 | 0.83 | GRM2 (0.39) | TNKS2CYP1A2CYP3A4NT5ECTSD | |
| SCHEMBL12059074 | 0.79 | LMNA (0.38) | TNKS2BCL2A1BACE1 | |
| SCHEMBL6921125 | 0.79 | RAB9A (0.40) | GSK3AGSK3BCYP1A2CYP3A4 | |
| SCHEMBL12059019 | 0.78 | CTSD (0.36) | TNKS2CTSDBCL2A1BACE1MAP4K4 | |
| SCHEMBL12059079 | 0.78 | BCL2A1 (0.38) | CYP1A2CYP3A4CTSDBCL2A1 | |
| SCHEMBL6922345 | 0.77 | HTR1A (0.41) | TNKS2MAP4K4 | |
| SCHEMBL6920638 | 0.76 | RAB9A (0.38) | GSK3AGSK3BCYP1A2CYP3A4 | |
| SCHEMBL6920625 | 0.76 | APOBEC3A (0.37) | GSK3AGSK3BTNKS2CYP1A2CYP3A4 | |
| SCHEMBL12059544 | 0.76 | GRM2 (0.37) | CYP1A2CYP3A4CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |